FDA Requires Pharma Firms to File Electronically

Feb 13, 2017

RAPS

The countdown begins starting May 5, pharmaceutical, biologic and generic manufacturers will have to submit to the U.S. FDA Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) all New Drug Applications (NDAs), Biologics License Application (BLAs) and Abbreviated New Drug Applications (ANDAs) using the electronic Common Technical Document (eCTD).

Drug Master Files (DMFs), Biological Product Files (BPFs) and other master files also have to meet the May 5th deadline for transitioning to the eCTD. The only exemptions that will be allowed will be for single patient compassionate use investigational new drug applications (INDs) and academic-initiated INDs, according to Regulatory Affairs Professionals Society.

The eCTD is designed to make regulatory submissions easier and more efficient by requiring a common global standard for companies to electronically submit the quality, safety and efficacy information required for approval to the regulatory agencies in the United States, EU, Canada and Japan, says RAPS.

Internationally, the eCTD has been required for Centralized Procedure applications to the European Medicines Agency (EMA) since 2010.

Read the RAPS story

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments